AlphaDERA Labs Nabs FDA Emergency Use Authorization for COVID-19 RT-PCR Test
July 24, 2023
![](https://assets-global.website-files.com/63a2265a2c89457a7b7e057b/651c9e0e3200e177e449b749_AlphaDera%20Labs%20Nabs%20FDA%20Emergency%20Use%20Authorization%20for%20COVID-19%20RT-PCR%20Test.webp)
AlphaDERA Labs obtained Emergency Use Authorization from the US Food and Drug Administration last week for a PCR assay to detect SARS-CoV-2.
The assay, named Alphadx SARS-CoV-2 RT-PCR Test, is authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal and mid-turbinate nasal swab specimens from individuals suspected of having COVID-19 by their healthcare provider.
Testing is limited to AlphaDERA's CLIA facility, which is authorized to perform high-complexity testing, according to the FDA's letter of authorization.
Based in Houston, AlphaDERA offers COVID-19 testing for healthcare providers, travelers, individual patients, and public or private organizations, according to the company’s website.